Advertisement Edgeline Holdings to become Oncolin Therapeutics - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Edgeline Holdings to become Oncolin Therapeutics

Edgeline Holdings has made a strategic business change to focus exclusively on its biotech business and is changing its name to Oncolin Therapeutics.

This decision comes after its recent acquisition of Intertech Bio which has propelled the company into the multi-billion dollar biotechnology industry through the addition of significant partnerships and the hiring of key personnel. The company will immediately suspend its other business that is not associated with biotechnology.